Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinded randomized trial of intravenous Ferrlecit in iron-deficient patients undergoing TAVI
MOH_2020-10-18_009407Phase 4Not yet recruiting
- Sponsor
- ארז מרקוסון
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of sodium ferric gluconate in iron deficiency anemia (IDA) (2 arms), sponsored by ארז מרקוסון. Primary endpoint: Functional status at 40 days after TAVI. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
sodium ferric gluconate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on MOH_2020-10-18_009407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-18_009407.